Prothena Corporation plc
Feb 19, 2015

Prothena to Report Fourth Quarter and Full Year 2014 Financial Results and Host Webcast and Conference Call on March 5

DUBLIN, Ireland, Feb. 19, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, announced today that it will report its fourth quarter and full year 2014 financial results on Thursday, March 5, 2015, after the close of the U.S. financial markets. The announcement will be followed by a live audio webcast and conference call at 4:30 p.m. ET.

The webcast will be made available on the Company's website at www.prothena.com under the Investors tab in the Events and Presentations section. Following the live audio webcast, a replay will be available on the Company's website for 90 days.

To access the conference call via dial-in, please dial (877) 887-5215 (U.S. toll free) or (315) 625-3069 (international) five minutes prior to the start time and refer to conference ID number 82696406. A replay of the call will be available until March 12, 2015 via dial-in at (855) 859-2056 (U.S. toll free) or (404) 537-3406 (international), Conference ID Number 82696406.

About Prothena

Prothena Corporation plc is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. The Company is developing antibody-based product candidates that target a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002) and psoriasis and other inflammatory diseases (PRX003).

For more information, please visit the Company's website at www.prothena.com.

CONTACT: Investors: Tran Nguyen, CFO

         650-837-8535, IR@prothena.com

         Media: Angela Bitting

         925-202-6211, angela.bitting@prothena.com